144 related articles for article (PubMed ID: 29997388)
21. Phenotype based prediction of exome sequencing outcome using machine learning for neurodevelopmental disorders.
Dingemans AJM; Hinne M; Jansen S; van Reeuwijk J; de Leeuw N; Pfundt R; van Bon BW; Vulto-van Silfhout AT; Kleefstra T; Koolen DA; van Gerven MAJ; Vissers LELM; de Vries BBA
Genet Med; 2022 Mar; 24(3):645-653. PubMed ID: 34906484
[TBL] [Abstract][Full Text] [Related]
22. A head-to-head evaluation of the diagnostic efficacy and costs of trio versus singleton exome sequencing analysis.
Tan TY; Lunke S; Chong B; Phelan D; Fanjul-Fernandez M; Marum JE; Kumar VS; Stark Z; Yeung A; Brown NJ; Stutterd C; Delatycki MB; Sadedin S; Martyn M; Goranitis I; Thorne N; Gaff CL; White SM
Eur J Hum Genet; 2019 Dec; 27(12):1791-1799. PubMed ID: 31320747
[TBL] [Abstract][Full Text] [Related]
23. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers.
Graf MD; Needham DF; Teed N; Brown T
Per Med; 2013 May; 10(3):235-243. PubMed ID: 29768740
[TBL] [Abstract][Full Text] [Related]
24.
Roston A; Evans D; Gill H; McKinnon M; Isidor B; Cogné B; Mwenifumbo J; van Karnebeek C; An J; Jones SJM; Farrer M; Demos M; Connolly M; Gibson WT; ;
J Med Genet; 2021 Mar; 58(3):196-204. PubMed ID: 32546566
[TBL] [Abstract][Full Text] [Related]
25. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
[TBL] [Abstract][Full Text] [Related]
26. Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.
Cheng JS; Lee MJ; Massicotte E; Ashman B; Gruenberg M; Pilcher LE; Skelly AC
Spine (Phila Pa 1976); 2011 Oct; 36(21 Suppl):S144-63. PubMed ID: 21952186
[TBL] [Abstract][Full Text] [Related]
27. Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers.
Tabbaa SM; Crawford DC; Provencher M; Farr J; Bugbee WD
Arthrosc Sports Med Rehabil; 2022 Dec; 4(6):e2107-e2113. PubMed ID: 36579033
[TBL] [Abstract][Full Text] [Related]
28. Health technology assessment and private payers's coverage of personalized medicine.
Trosman JR; Van Bebber SL; Phillips KA
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
[TBL] [Abstract][Full Text] [Related]
29. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.
Trosman JR; Van Bebber SL; Phillips KA
J Oncol Pract; 2010 Sep; 6(5):238-42. PubMed ID: 21197187
[TBL] [Abstract][Full Text] [Related]
30. Whole Exome Sequencing in Pediatric Neurology Patients: Clinical Implications and Estimated Cost Analysis.
Nolan D; Carlson M
J Child Neurol; 2016 Jun; 31(7):887-94. PubMed ID: 26863999
[TBL] [Abstract][Full Text] [Related]
31. Characterizing health plan evidence review practices.
Panzer AD; Enright DE; Graff J; Chambers JD
J Manag Care Spec Pharm; 2022 Sep; 28(9):1053-1058. PubMed ID: 36001106
[No Abstract] [Full Text] [Related]
32. Poor evidence is used to support commercial payers' coverage policies for shoulder arthroplasty.
Sudah SY; Faccone RD; Imam N; Patankar A; Manzi JE; Menendez ME; Nicholson A
J Shoulder Elbow Surg; 2023 Nov; 32(11):2222-2231. PubMed ID: 37247779
[TBL] [Abstract][Full Text] [Related]
33. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study.
Dragojlovic N; Elliott AM; Adam S; van Karnebeek C; Lehman A; Mwenifumbo JC; Nelson TN; du Souich C; Friedman JM; Lynd LD
Genet Med; 2018 Sep; 20(9):1013-1021. PubMed ID: 29300375
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with the time to complete clinical exome sequencing in a pediatric patient population.
Lee G; Yu L; Suarez CJ; Stevenson DA; Ling A; Killer L
Genet Med; 2022 Oct; 24(10):2028-2033. PubMed ID: 35951015
[TBL] [Abstract][Full Text] [Related]
35. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.
Trosman JR; Weldon CB; Kelley RK; Phillips KA
J Natl Compr Canc Netw; 2015 Mar; 13(3):311-8. PubMed ID: 25736008
[TBL] [Abstract][Full Text] [Related]
36. Utility and limitations of exome sequencing as a genetic diagnostic tool for conditions associated with pediatric sudden cardiac arrest/sudden cardiac death.
Li MH; Abrudan JL; Dulik MC; Sasson A; Brunton J; Jayaraman V; Dugan N; Haley D; Rajagopalan R; Biswas S; Sarmady M; DeChene ET; Deardorff MA; Wilkens A; Noon SE; Scarano MI; Santani AB; White PS; Pennington J; Conlin LK; Spinner NB; Krantz ID; Vetter VL
Hum Genomics; 2015 Jul; 9(1):15. PubMed ID: 26187847
[TBL] [Abstract][Full Text] [Related]
37. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.
Lu CY; Loomer S; Ceccarelli R; Mazor KM; Sabin J; Clayton EW; Ginsburg GS; Wu AC
J Pers Med; 2018 May; 8(2):. PubMed ID: 29772692
[TBL] [Abstract][Full Text] [Related]
38. Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature.
Torti E; Keren B; Palmer EE; Zhu Z; Afenjar A; Anderson IJ; Andrews MV; Atkinson C; Au M; Berry SA; Bowling KM; Boyle J; Buratti J; Cathey SS; Charles P; Cogne B; Courtin T; Escobar LF; Finley SL; Graham JM; Grange DK; Heron D; Hewson S; Hiatt SM; Hibbs KA; Jayakar P; Kalsner L; Larcher L; Lesca G; Mark PR; Miller K; Nava C; Nizon M; Pai GS; Pappas J; Parsons G; Payne K; Putoux A; Rabin R; Sabatier I; Shinawi M; Shur N; Skinner SA; Valence S; Warren H; Whalen S; Crunk A; Douglas G; Monaghan KG; Person RE; Willaert R; Solomon BD; Juusola J
Genet Med; 2019 Sep; 21(9):2036-2042. PubMed ID: 30739909
[TBL] [Abstract][Full Text] [Related]
39. Whole-exome Sequencing Helps the Diagnosis and Treatment in Children with Neurodevelopmental Delay Accompanied Unexplained Dyspnea.
Tong W; Wang Y; Lu Y; Ye T; Song C; Xu Y; Li M; Ding J; Duan Y; Zhang L; Gu W; Zhao X; Yang XA; Jin D
Sci Rep; 2018 Mar; 8(1):5214. PubMed ID: 29581464
[TBL] [Abstract][Full Text] [Related]
40. National Private Payer Coverage of Prostate MRI.
Booker MT; Silva E; Rosenkrantz AB
J Am Coll Radiol; 2019 Jan; 16(1):24-29. PubMed ID: 30213713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
